TRIL Stock Forecast. TRIL Stock Forecast - Get a free TRIL stock predictions and find out whether you should buy or sell TRIL stock. The trend analysis tool will help you make a … Trillium Therapeutics Inc. Stock Price (TRIL) | Barron's Nov 08, 2019 · View today's stock price, news and analysis for Trillium Therapeutics Inc. (TRIL). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation Is Trillium Therapeutics Inc. (NASDAQ:TRIL) Still Worth A ... Mar 03, 2020 · 3 out of 4 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Trillium Therapeutics Inc.. 0 analysts has assigned a Sell rating on the TRIL stock. The 12-month mean consensus price target for the company’s shares has been set at $11.02.
TRIL Stock Forecast | TRIL Stock Predictions
23 Nov 2017 Transformers & Recti Share Price Live - 5.90, Transformers & Recti Stock Price, Today - The Economic Times. Do Not Sell My Personal Information · Terms and Conditions. © 1995 - 2020 The Motley Fool. All rights reserved. Market data powered by FactSet and Web 17 Jan 2020 The consortium consists of the Tata-owned TRIL Urban Transport, an affiliate of Singaporean wealth fund GIC and Hong Kong-based SSG Stock analysis for Trillium Therapeutics Inc (TRIL:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 3 Jan 2020 penny stocks to buy or sell right now performed impressively over the course of the past two weeks is Pacific Ethanol (TRIL Stock Report).
TRIL Price Target and Analyst Ratings (Trillium Therapeutics)
Get the latest Trillium Therapeutics Inc. TRIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. and a bulleted list of reasons to buy or sell the stock. It also TRIL Stock Forecast - Buy or Sell? Trillium Therapeutics Inc. Sell Candidate Downgraded TRIL Stock Evaluation. The Trillium Therapeutics Inc. stock holds several negative signals and despite the positive trend we believe Trillium Therapeutics Inc. will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.